JP2018533373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533373A5 JP2018533373A5 JP2018541524A JP2018541524A JP2018533373A5 JP 2018533373 A5 JP2018533373 A5 JP 2018533373A5 JP 2018541524 A JP2018541524 A JP 2018541524A JP 2018541524 A JP2018541524 A JP 2018541524A JP 2018533373 A5 JP2018533373 A5 JP 2018533373A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- lymphocytes
- absence
- culturing
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 14
- 210000004698 lymphocyte Anatomy 0.000 claims 10
- 238000012258 culturing Methods 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 230000003394 haemopoietic effect Effects 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000002919 epithelial cell Anatomy 0.000 claims 3
- 210000002950 fibroblast Anatomy 0.000 claims 3
- 210000002536 stromal cell Anatomy 0.000 claims 3
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021147372A JP7451468B2 (ja) | 2015-10-30 | 2021-09-10 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
| JP2024033438A JP2024069306A (ja) | 2015-10-30 | 2024-03-06 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1519198.4 | 2015-10-30 | ||
| GBGB1519198.4A GB201519198D0 (en) | 2015-10-30 | 2015-10-30 | Expansion of gamma delta t cells resident in non-haematopoietic tissue and uses of these cells |
| GB1612731.8 | 2016-07-22 | ||
| GBGB1612731.8A GB201612731D0 (en) | 2016-07-22 | 2016-07-22 | Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells |
| PCT/EP2016/076264 WO2017072367A1 (en) | 2015-10-30 | 2016-10-31 | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147372A Division JP7451468B2 (ja) | 2015-10-30 | 2021-09-10 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018533373A JP2018533373A (ja) | 2018-11-15 |
| JP2018533373A5 true JP2018533373A5 (enExample) | 2019-10-24 |
Family
ID=57211532
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541524A Pending JP2018533373A (ja) | 2015-10-30 | 2016-10-31 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
| JP2021147372A Active JP7451468B2 (ja) | 2015-10-30 | 2021-09-10 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
| JP2024033438A Pending JP2024069306A (ja) | 2015-10-30 | 2024-03-06 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147372A Active JP7451468B2 (ja) | 2015-10-30 | 2021-09-10 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
| JP2024033438A Pending JP2024069306A (ja) | 2015-10-30 | 2024-03-06 | 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11618885B2 (enExample) |
| EP (2) | EP3368658B1 (enExample) |
| JP (3) | JP2018533373A (enExample) |
| KR (2) | KR20250093576A (enExample) |
| CN (1) | CN108473958A (enExample) |
| AU (2) | AU2016344779B2 (enExample) |
| CA (1) | CA3003077A1 (enExample) |
| DK (1) | DK3368658T3 (enExample) |
| ES (1) | ES2925261T3 (enExample) |
| IL (3) | IL295838B2 (enExample) |
| MX (2) | MX2018005207A (enExample) |
| MY (1) | MY198084A (enExample) |
| PH (1) | PH12018500926A1 (enExample) |
| PL (1) | PL3368658T3 (enExample) |
| PT (1) | PT3368658T (enExample) |
| WO (1) | WO2017072367A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| EP3681996B1 (en) | 2017-09-15 | 2024-08-07 | King's College London | Compositions and methods for enhancing gamma delta t cells in the gut |
| CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
| GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| WO2020027193A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人三重大学 | γδ型Ｔ細胞への遺伝子導入方法 |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CN113423820A (zh) * | 2018-11-08 | 2021-09-21 | 伽马三角洲疗法有限公司 | 分离和扩增细胞的方法 |
| PH12021551475A1 (en) | 2019-01-07 | 2022-05-02 | Shattuck Labs Inc | Heterodimeric proteins for modulating gamma delta t cells |
| US11098093B2 (en) | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| CN112029719B (zh) * | 2019-06-04 | 2024-05-03 | 北京医明佳和生物科技有限公司 | 纯化的双阴性t细胞及其制备和应用 |
| WO2021016652A1 (en) * | 2019-07-29 | 2021-02-04 | The University Of Melbourne | METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS |
| JP2022545196A (ja) | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP7764364B2 (ja) | 2019-08-16 | 2025-11-05 | ガンマデルタ セラピューティクス リミティッド | エクスビボγδ Ｔ細胞集団 |
| CN115151565A (zh) | 2019-10-31 | 2022-10-04 | 莫佛塞斯公司 | 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 |
| EP4114415A1 (en) | 2020-03-06 | 2023-01-11 | Sorrento Therapeutics, Inc. | Innate immunity killer cells targeting psma positive tumor cells |
| KR20230013022A (ko) | 2020-03-20 | 2023-01-26 | 감마델타 테라퓨틱스 엘티디 | 골수성 악성종양의 치료를 위한 v 델타1+ t 세포 |
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| PL4269444T3 (pl) | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| GB202013962D0 (en) | 2020-09-04 | 2020-10-21 | Gammadelta Therapeutics Ltd | Immunotherapy composition |
| AU2022224391A1 (en) | 2021-02-17 | 2023-08-24 | Gammadelta Therapeutics Ltd | Anti-tcr delta variable 1 antibodies |
| GB202105113D0 (en) | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| CA3228168A1 (en) | 2021-08-03 | 2023-02-09 | Gammadelta Therapeutics Ltd | Engineering of gamma delta t cells and compositions thereof |
| WO2023053994A1 (ja) * | 2021-09-29 | 2023-04-06 | アイ ピース， インコーポレイテッド | 幹細胞の製造方法 |
| CA3208653A1 (en) | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| JPWO2023176896A1 (enExample) * | 2022-03-18 | 2023-09-21 | ||
| EP4504247A1 (en) | 2022-04-04 | 2025-02-12 | Gammadelta Therapeutics Ltd | Novel gene armoring |
| WO2024209429A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | T cells for use in treating relapsed or refractory acute myeloid leukemia |
| CN121532496A (zh) | 2023-07-20 | 2026-02-13 | 武田药品工业株式会社 | 用于制备γδT细胞的无网格方法 |
| CN118165933B (zh) * | 2024-05-14 | 2024-07-16 | 成都美杰赛尔生物科技有限公司 | 组合物、提高cd39-cd69-t细胞比例的方法 |
| WO2026013159A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| WO2026013158A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| CN118853566B (zh) * | 2024-09-26 | 2025-05-09 | 青岛华赛伯曼医学细胞生物有限公司 | 一种肿瘤浸润淋巴细胞的培养方法及培养基 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE421573T1 (de) | 1998-11-04 | 2009-02-15 | Therapure Biopharma Inc | Verfahren zur herstellung von gamma delta t zellen |
| US20060246520A1 (en) * | 2003-05-23 | 2006-11-02 | Institut National De La Sante Et De La Recherche Medicale | Gamma delta t cell-mediated therapy |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| WO2009131730A2 (en) * | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| PT2710123T (pt) * | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| EP3060059A4 (en) | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| RU2739770C2 (ru) * | 2014-06-11 | 2020-12-28 | полибайосепт ГмбХ | Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии |
| CN104293734B (zh) * | 2014-09-28 | 2018-01-09 | 上海云舜生物技术有限公司 | 一种人γδT细胞的制备方法 |
| CN104711224A (zh) * | 2015-01-09 | 2015-06-17 | 天津大学 | 一种提高人Vδ2T细胞扩增效率的体外培养方法及应用 |
| AU2016274633B2 (en) * | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| WO2016198906A1 (fr) * | 2015-06-10 | 2016-12-15 | Arcelormittal | Acier a haute résistance et procédé de fabrication |
-
2016
- 2016-10-31 WO PCT/EP2016/076264 patent/WO2017072367A1/en not_active Ceased
- 2016-10-31 KR KR1020257019399A patent/KR20250093576A/ko active Pending
- 2016-10-31 IL IL295838A patent/IL295838B2/en unknown
- 2016-10-31 PT PT167885391T patent/PT3368658T/pt unknown
- 2016-10-31 US US15/771,875 patent/US11618885B2/en active Active
- 2016-10-31 IL IL315329A patent/IL315329A/en unknown
- 2016-10-31 MY MYPI2018000604A patent/MY198084A/en unknown
- 2016-10-31 CN CN201680074800.5A patent/CN108473958A/zh active Pending
- 2016-10-31 DK DK16788539.1T patent/DK3368658T3/da active
- 2016-10-31 CA CA3003077A patent/CA3003077A1/en active Pending
- 2016-10-31 KR KR1020187015244A patent/KR102821381B1/ko active Active
- 2016-10-31 PL PL16788539.1T patent/PL3368658T3/pl unknown
- 2016-10-31 MX MX2018005207A patent/MX2018005207A/es unknown
- 2016-10-31 EP EP16788539.1A patent/EP3368658B1/en active Active
- 2016-10-31 EP EP22182997.1A patent/EP4148124A1/en active Pending
- 2016-10-31 JP JP2018541524A patent/JP2018533373A/ja active Pending
- 2016-10-31 AU AU2016344779A patent/AU2016344779B2/en active Active
- 2016-10-31 ES ES16788539T patent/ES2925261T3/es active Active
-
2018
- 2018-04-26 IL IL258985A patent/IL258985B2/en unknown
- 2018-04-26 MX MX2022011003A patent/MX2022011003A/es unknown
- 2018-04-30 PH PH12018500926A patent/PH12018500926A1/en unknown
-
2021
- 2021-09-10 JP JP2021147372A patent/JP7451468B2/ja active Active
-
2022
- 2022-09-29 US US17/936,811 patent/US20230099491A1/en active Pending
- 2022-12-09 AU AU2022283768A patent/AU2022283768A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033438A patent/JP2024069306A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533373A5 (enExample) | ||
| Abel et al. | Natural killer cells: development, maturation, and clinical utilization | |
| Somanchi et al. | Engineering lymph node homing of ex vivo–expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7 | |
| Ye et al. | The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells | |
| Crompton et al. | Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy | |
| Ducimetière et al. | The interplay between innate lymphoid cells and the tumor microenvironment | |
| Zhou et al. | Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo | |
| Nojima et al. | In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo | |
| MY198084A (en) | Expansion of non-haematopoietic tissue-resident ()()t cells and uses of these cells | |
| Cella et al. | Beyond NK cells: the expanding universe of innate lymphoid cells | |
| Lysakova-Devine et al. | Tissue-specific NK cell populations and their origin | |
| JP2020518289A5 (enExample) | ||
| Lees et al. | Generation, persistence and plasticity of CD4 T‐cell memories | |
| Najar et al. | Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the T cell response: the importance of the IL-10/CD210 axis | |
| KR101706524B1 (ko) | 안정성 높은 자연살해세포의 효율적인 제조방법 | |
| JP5118624B2 (ja) | 新規なヒトｔ細胞集団 | |
| IL187628A (en) | Method of culturing human embryonic stem cells into dendritic cells | |
| Murphy et al. | Natural killer cells and bone marrow transplantation | |
| Luo et al. | New insights into the stemness of adoptively transferred T cells by γc family cytokines | |
| Kumar et al. | Multiplexed iPSC platform for advanced NK cell immunotherapies | |
| Batten et al. | Immune response to stem cells and strategies to induce tolerance | |
| JP2023504734A5 (enExample) | ||
| US20260034218A1 (en) | Alleviating graft versus host disease using engineered inkt cells | |
| US9752128B2 (en) | Methods of generating cells exhibiting phenotypic plasticity | |
| Coghill et al. | The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting |